Daily Newsletter

26 September 2024

Daily Newsletter

26 September 2024

Orion and Aitia partner for AI-driven oncology drug discovery

Aitia is entitled to receive milestone payments exceeding $10m per drug target.

Vishnu Priyan September 26 2024

Finnish pharmaceutical company Orion has entered a partnership with Aitia to leverage artificial intelligence in drug discovery and simulation in the oncology field.

Through their collaboration, the companies aim to develop new Gemini Digital Twins - innovative tools designed to enhance cancer treatment strategies.

Orion and Aitia will leverage the Digital Twins technology of Aitia along with Orion's extensive pre-clinical and clinical expertise to discover and validate new drug targets.

Their collaboration is set to address translational questions and develop drug candidates for multiple cancer indications.

Orion innovative medicines and research and development senior vice-president Outi Vaarala stated: “We are excited to collaborate with Aitia to harness the power of their Gemini Digital Twins and Causal AI technology in the discovery and development of new cancer treatments.

“By leveraging their cutting-edge technology, we aim to unlock deeper insights into the complex biology of cancer, ultimately accelerating the development of novel therapies that could significantly improve patient outcomes.”

Orion has secured an exclusive option for the research, development and commercialisation of new drug candidates against the targets chosen by Aitia.

Aitia is entitled to upfront payments and milestone payments on meeting development and regulatory goals.

Milestone payments can exceed $10m per drug target.

Aitia will earn tiered single-digit royalty payments on the sales of products developed through the partnership.

Aitia CEO and co-founder Colin Hill stated: “Our collaboration with Orion is particularly exciting as it brings together our Gemini Digital Twins which leverage large quantities of multi-omic patient data and causal AI and simulation with Orion’s deep expertise in oncology drug discovery and development.

“By creating highly accurate and predictive models of disease, we can uncover previously hidden mechanisms and pathways, accelerating the discovery of new, more effective medicines.”

In July 2024, Orion and MSD announced that the agreement for the co-development and co-commercialisation of opevesostat (MK-5684/ODM-208) has changed to give MSD exclusive rights to the asset.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close